ProQR Therapeutics N.V.

ProQR Therapeutics N.V.verified

PRQR

Price:

$1.825

Market Cap:

$134.04M

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and researc...[Read more]

Industry

Biotechnology

IPO Date

2014-09-18

Stock Exchange

NASDAQ

Ticker

PRQR

The Enterprise Value as of September 2024 (TTM) for ProQR Therapeutics N.V. (PRQR) is 72.68M

According to ProQR Therapeutics N.V.’s latest financial reports and current stock price. The company's current Enterprise Value is 72.68M. This represents a change of 42.54% compared to the average of 50.99M of the last 4 quarters.

ProQR Therapeutics N.V. (PRQR) Historical Enterprise Value (quarterly & annually)

How has PRQR Enterprise Value performed in the past?

The mean historical Enterprise Value of ProQR Therapeutics N.V. over the last ten years is 158.18M. The current 72.68M Enterprise Value has changed 4.49% with respect to the historical average. Over the past ten years (40 quarters), PRQR's Enterprise Value was at its highest in in the September 2018 quarter at 476.92M. The Enterprise Value was at its lowest in in the March 2022 quarter at -48810476.85.

Quarterly (TTM)
Annual

Average

158.18M

Median

113.51M

Minimum

28.90M

Maximum

372.37M

ProQR Therapeutics N.V. (PRQR) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of ProQR Therapeutics N.V. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 1.19%

Maximum Annual Enterprise Value = 372.37M

Minimum Annual Increase = -73.77%

Minimum Annual Enterprise Value = 28.90M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202345.84M-73.77%
2022174.75M-46.22%
2021324.95M149.06%
2020130.47M-50.63%
2019264.25M-29.04%
2018372.37M1.19%
201728.90M-47.58%
201655.13M-42.90%
201596.55M9.00%
201488.57M-62.67%

ProQR Therapeutics N.V. (PRQR) Average Enterprise Value

How has PRQR Enterprise Value performed in the past?

The current Enterprise Value of ProQR Therapeutics N.V. (PRQR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

181.85M

5-year avg

188.05M

10-year avg

158.18M

ProQR Therapeutics N.V. (PRQR) Enterprise Value vs. Peers

How is PRQR’s Enterprise Value compared to its peers?

ProQR Therapeutics N.V.’s Enterprise Value is less than Annexon, Inc. (623.57M), less than Arrowhead Pharmaceuticals, Inc. (2.95B), less than Day One Biopharmaceuticals, Inc. (975.18M), less than Terns Pharmaceuticals, Inc. (575.17M), less than Alnylam Pharmaceuticals, Inc. (36.46B), less than Wave Life Sciences Ltd. (616.48M), less than Blueprint Medicines Corporation (6.14B), less than Apellis Pharmaceuticals, Inc. (4.49B), less than Assembly Biosciences, Inc. (95.68M), greater than Spero Therapeutics, Inc. (14.38M), greater than Achilles Therapeutics plc (-61656377.00), less than Instil Bio, Inc. (501.98M), greater than Neoleukin Therapeutics, Inc. (-6333315.00), greater than CytomX Therapeutics, Inc. (63.80M), greater than NextCure, Inc. (21.40M), less than Nuvation Bio Inc. (1.01B),

Build a custom stock screener for ProQR Therapeutics N.V. (PRQR) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ProQR Therapeutics N.V. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

ProQR Therapeutics N.V. (PRQR) and other stocks custom spreadsheet templates

The easiest way to analyze a company like ProQR Therapeutics N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is ProQR Therapeutics N.V.'s Enterprise Value?

What is the highest Enterprise Value for ProQR Therapeutics N.V. (PRQR)?

What is the 3-year average Enterprise Value for ProQR Therapeutics N.V. (PRQR)?

What is the 5-year average Enterprise Value for ProQR Therapeutics N.V. (PRQR)?

How does the current Enterprise Value for ProQR Therapeutics N.V. (PRQR) compare to its historical average?